Research programme: cell-based therapeutics - SELECT Therapeutics/Cytomatrix
Alternative Names: Cell-based therapeutics research programme - SELECT Therapeutics/CytomatrixLatest Information Update: 01 Feb 2017
At a glance
- Originator Unknown
- Developer Cytomatrix; SELECT Therapeutics (CEASED)
- Class Cell therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer
Most Recent Events
- 31 Jan 2017 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 31 Jan 2017 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 11 Nov 2002 Suspended - Preclinical for Autoimmune disorders in USA (unspecified route)